Shares of Replimune Group REPL have surged 131.1% over the past three months, fueled by positive regulatory updates. In October, the FDA accepted the resubmission of the biologics license application ...
Replimune Group is focused on developing immunotherapies using oncolytic viruses—engineered viruses that target and kill cancer cells while stimulating a patient’s immune response. Its lead product ...
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies.
Replimune Group ( (REPL)) has released its Q2 earnings. Here is a breakdown of the information Replimune Group presented to its investors. Replimune Group, Inc. is a clinical-stage biotechnology ...
WOBURN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, ...
Jefferies analyst Roger Song maintained a Buy rating on Replimune Group (REPL - Research Report) yesterday and set a price target of $49.00. The companys shares closed yesterday at $23.09. According ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
On Tuesday, Replimune Group Inc . (NASDAQ:REPL), currently trading at $11.70, saw its price target increased to $27.00 from $18.00 by BMO Capital, with the firm maintaining an Outperform rating on the ...
Hosted on MSN
Wall Street analysts predict a 65.72% upside in Replimune Group (REPL): Here's what you should know
Shares of Replimune Group, Inc. (REPL) have gained 0.7% over the past four weeks to close the last trading session at $7.76, but there could still be a solid upside left in the stock if short-term ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results